NICE gives RoActemra another chance for rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
NICE, the health technology assessment body for England and Wales, says that with extra data from Roche it might recommend the firm's RoActemra (tocilizumab) for some NHS patients with rheumatoid arthritis in its final guidance.